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ARTICLE
Contrasting requirements during disease evolution
identify EZH2 as a therapeutic target in AML
Faisal Basheer1,2,3*, George Giotopoulos1,2,3*, Eshwar Meduri1,2,3, Haiyang Yun1,2,3, Milena Mazan1,4, Daniel Sasca1,2,3, Paolo Gallipoli1,2,3,
Ludovica Marando1,2,3, Malgorzata Gozdecka1,4, Ryan Asby1,2,3, Olivia Sheppard1,2,3, Monika Dudek4, Lars Bullinger5, Hartmut Do¨hner6,
Richard Dillon7, Sylvie Freeman8, Oliver Ottmann9, Alan Burnett10, Nigel Russell11, Elli Papaemmanuil12, Robert Hills13, Peter Campbell4,
George S. Vassiliou1,2,4, and Brian J.P. Huntly1,2,3
Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function EZH2 mutations are common in
myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the evolution of acute myeloid
leukemia (AML), where we observed stage-speciﬁc and diametrically opposite functions for Ezh2 at the early and late stages
of disease. During disease maintenance, WT Ezh2 exerts an oncogenic function that may be therapeutically targeted. In
contrast, Ezh2 acts as a tumor suppressor during AML induction. Transcriptional analysis explains this apparent paradox,
demonstrating that loss of Ezh2 derepresses different expression programs during disease induction and maintenance.
During disease induction, Ezh2 loss derepresses a subset of bivalent promoters that resolve toward gene activation, inducing a
feto-oncogenic program that includes genes such as Plag1, whose overexpression phenocopies Ezh2 loss to accelerate AML
induction in mouse models. Our data highlight the importance of cellular context and disease phase for the function of Ezh2
and its potential therapeutic implications.
Introduction
Acute myeloid leukemia (AML) is an aggressive hematological
cancer with a dismal outlook (Ferrara and Schiffer, 2013). Re-
cently, characterization of the mutational landscape of AML has
allowed for a deeper understanding of its biology (Grimwade
et al., 2016; Papaemmanuil et al., 2016) and the identiﬁcation
of potentially sensitive genotypes, facilitating the development
of novel agents that target them and providing promise of
improved outcomes (Daigle et al., 2011; Dawson et al., 2011,
2012; Basheer and Huntly, 2015; Gallipoli et al., 2015, 2018;
Giotopoulos et al., 2016). Enhancer of zeste homologue 2 (EZH2)
forms the core of the multiprotein Polycomb repressive complex
2 (PRC2; Margueron and Reinberg, 2011). It is responsible for the
transcriptional repression of target genes by depositing di- and
trimethylation on lysine 27 of histone 3 (H3K27me3) through its
catalytic SET domain at proximal and distal regulatory elements
(Cao et al., 2002; Kuzmichev et al., 2002), with the H3K27me3
mark repressing gene expression through a number of mecha-
nisms (Wang et al., 2004; Barski et al., 2007; Hansen et al., 2008;
Simon and Kingston, 2013). Aberrant EZH2 expression and
activity have also been linked to tumorigenesis; EZH2was found
to be overexpressed in breast, prostate, and renal cancers, where
its levels correlate with poor prognosis (Varambally et al., 2002;
Kleer et al., 2003; Wagener et al., 2008). Gain-of-function mu-
tations of EZH2 at codon Y641 have also been described in be-
tween 7% and 22% of patients with follicular lymphoma and
diffuse large B cell lymphomas, respectively (Morin et al., 2010),
and promising preclinical efﬁcacy with small-molecule in-
hibitors of EZH2 methyltransferase activity has led to ongoing
phase 1 trials (NCT02082977, NCT01897571, and NCT02395601),
the results of which are awaited. In contrast, the role of EZH2 in
myeloid malignancies is less well deﬁned and at ﬁrst glance
counterintuitive. Predominantly hemizygous, predicted loss-of-
function mutations have been described at low frequency in
myeloid malignancies, including myeloproliferative neoplasms
(MPNs), myelodysplasia (MDS), and AML (Ernst et al., 2010;
Makishima et al., 2010; Nikoloski et al., 2010; Ley et al., 2013),
and Ezh2 loss in mouse models has been shown to lead to the de-
velopment of multiple long-latency hematological malignancies,
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predominantly MDS, MPN, and T-adult lymphoblastic leukemia/
T cell lymphoma (Simon et al., 2012; Mochizuki-Kashio et al.,
2015). Moreover, loss of Ezh2 accelerates the development of my-
eloﬁbrosis and decreases survival in Jak2-V617F–driven MPN
(Sashida et al., 2016; Shimizu et al., 2016; Yang et al., 2016) and
Runx1 mutated MDS (Sashida et al., 2014), identifying EZH2 as a
tumor suppressor. However, contrary to this role, reports have
also demonstrated that EZH2 is required for chronic myeloid
leukemia stem cell function (Scott et al., 2016; Xie et al., 2016), and
two separate studies have suggested that maintenance ofMLL-AF9
AML is reliant on Ezh2 (Neff et al., 2012; Tanaka et al., 2012),
suggesting EZH2 carries oncogenic function and is therefore a
plausible therapeutic target in this context. Given the counterin-
tuitive data on the function of EZH2 within myeloid malignancies,
we sought to explore this further in the context of AML and de-
lineate the role of EZH2 across different AML subtypes, as well as
during different phases of the disease. In this study, using genetic
and pharmacological models, we demonstrate that Ezh2 clearly has
contrasting roles at different disease stages—a tumor-suppressive
function during leukemogenesis and an oncogenic function during
leukemia maintenance—the ﬁrst such demonstration for an epi-
genetic regulator. Moreover, we provide mechanisms for its
tumor-suppressor role in our AML models and demonstrate a
minimal overlap between genes that mediate the tumor-
suppressive and oncogenic functions. Taken together, these
data provide reassurance that despite its tumor-suppressive ef-
fects during leukemogenesis, EZH2 may be a promising thera-
peutic target in established AML.
Results
Ezh2 is required for the maintenance of multiple
AML genotypes
To dissect the effects of Ezh2 loss during AML evolution, we
targeted EZH2 at various experimental time points using both
genetic ablation and pharmacological inhibition. We used ret-
roviral overexpression of two AML fusion oncogenes (MLL-AF9
and AML1-ETO9a) that generate separate and disparate models of
AML, are associated with a clinical range from good to poor
prognosis, and markedly differ in their mechanisms of leukemic
transformation. Initially focusing on the role of Ezh2 in AML
maintenance, we generated cell lines immortalized by retroviral
expression of MLL-AF9 or AML1-ETO9a in hematopoietic stem
and progenitor cells (HSPCs) from Ezh2ﬂ/ﬂ and WT mice.
Through retroviral expression of Cre (p-babe-Cre-puro or the
empty control vector p-babe-puro), we then deleted Ezh2, gen-
erating an Ezh2−/− and Ezh2+/+ genotype cellular background for
each oncogene, respectively (Fig. 1 a). Strikingly, we could
demonstrate that continued expression of Ezh2 was an absolute
requirement for the continued in vitro propagation of both
immortalized cell lines in serial methylcellulose replating ex-
periments (Fig. 1, b and c; and Fig. S1), with colony formation
completely abrogated in Ezh2−/− cells from the ﬁrst plating on-
ward. This was in stark contrast to empty vector–transduced
(Ezh2+/+) cells, which iteratively replated. Furthermore, the ef-
fects of Cre-mediated toxicity and/or low transduction efﬁ-
ciency were excluded as Cre-transduced Ezh2wt/wt; MLL-AF9 or
AML1-ETO9a–transformed cells were also able to repopulate and
form colonies adequately (Fig. S1 and data not shown).
To evaluate the role of Ezh2 in AMLmaintenance in vivo, and
therefore determine the therapeutic implications of targeting
EZH2 in established AML, we then generated primaryMLL-AF9
and AML1-ETO9a murine leukemias on an Ezh2ﬂ/ﬂ;Mx1-Cre
background but did not treat donor or recipient mice with
poly(I)-poly(C) (pIpC), thus leaving the Ezh2 locus intact
(Fig. 1 d). Secondary leukemias were then generated using
transplantation of primary splenic tissue into WT lethally irra-
diated recipients, and Ezh2 deletion was achieved in situ in the
test mice, following adequate engraftment, by the administra-
tion of pIpC (or PBS injections in the control arm) in recipient
mice. We were able to reproduce previous data that deletion of
Ezh2 signiﬁcantly disrupted the progression and prolonged
survival of secondary MLL-AF9 leukemias (Neff et al., 2012;
Tanaka et al., 2012). Moreover, and in keeping with our in vitro
ﬁndings, we extended this oncogenic role for Ezh2, further
demonstrating similar effects in AML1-ETO9a leukemias in vivo
(Fig. 1, e and f, respectively). There were no demonstrable dif-
ferences in disease bulk or pattern of inﬁltration between
Ezh2+/+ and Ezh2−/− recipient mice (Fig. S2). Of note, in the AML-
ETO9a Ezh2−/− cohort, only three of ten animals actually devel-
oped leukemia, with the other animals succumbing to either
thymic lymphomas or other nonleukemic causes of death only
after long latency (Table S1). Taken together, these data suggest
that Ezh2 displays oncogenic function across disparate subtypes
of established AML and suggest it as a possible therapeutic target
across AML subtypes.
Validation of EZH2 as a therapeutic target in AML models and
patient samples
To test this hypothesis, we next sought to examine the effects of
pharmacological inhibition of EZH2 in AML, using GSK343, an
S-adenosyl methionine–competitive EZH2 inhibitor (Verma
et al., 2012). Murine Ezh2+/+ MLL-AF9 spleen tumor cells cul-
tured in vitro demonstrated sensitivity to GSK343 with an IC50
(concentration where 50% maximal growth inhibition is ob-
served) of ∼10 µM (Fig. 2 a) and showed a signiﬁcant reduction
in colony size and formation in its presence compared with
vehicle control (Fig. 2 b). We correlated GSK343’s effects to di-
rect inhibition of EZH2 enzymatic function, demonstrating a
decrease in H3K27me3 in these tumor cells as early as 24 h after
treatment (Fig. 2 c). Consistent with our genetic studies, the
human AML1-ETO-fusion-driven cell line Kasumi-1 also dem-
onstrated increased sensitivity to GSK343 at similar IC50 to the
murine AML tumors (Fig. S3 a), with marked reduction in liquid
culture expansion compared with vehicle control (Fig. 2 d).
Functional analysis revealed that EZH2 inhibition with GSK343
resulted in a modest increase in apoptosis and G0/G1 cell cycle
arrest at 96 h into treatment (Fig. 2, e and f). Transformed Ezh2+/+
MLL-AF9 murine bone marrow (BM) HSPCs also had reduced
clonogenic potential with decreased colony formation when
treated with GSK343 (Fig. S3 b). We further tested EZH2 inhibi-
tion in primary leukemia cells isolated from patients across vari-
ous AML genotypes (n = 15; Fig. 2, g and h; and Fig. S3 c), where
signiﬁcant reduction of colony formation was seen, in contrast to
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Figure 1. Ezh2 functions as an oncogene during the maintenance of disparate subtypes of AML in vitro and in vivo. (a) Schema of the in vitro ex-
periments. (1) Ezh2ﬂ/ﬂ immortalized cell lines were generated from Ezh2ﬂ/ﬂ; WTmice at 8–12 wk of age via retroviral transduction withMLL-AF9 or AML1-ETO9a
individually and were allowed to immortalize over successive methylcellulose replatings. (2) Ezh2was excised in established preleukemic cell lines via a p-Babe-
Cre-puro vector (for deletion of Ezh2 in vitro) or a p-Babe-puro empty vector (control) and cultured ± puromycin in methylcellulose. (b and c) Methylcellulose
replatings for empty vector–transduced vs. p-babe-Cre-puro–transduced Ezh2ﬂ/ﬂ; MLL-AF9 immortalized murine c-kit+ BM HSPCs (b) and Ezh2ﬂ/ﬂ; AML1-ETO9a
(c) immortalized cell lines in the absence or presence of puromycin to select positively transduced cells. p-babe-Cre-puro–transduced cells fail to form colonies
and exhaust at the ﬁrst round of replating (while empty vector–transduced cells expand and form colonies on iterative replatings), indicating an absolute
requirement of Ezh2 for maintenance ofMLL-AF9 and AML1-ETO9a in vitro (n = 2 independent experiments). (d) Schematic diagram of the in vivo experimental
process. (1) Generate Ezh2ﬂ/ﬂ; Mx1-Cre+ primary leukemias: c-kit+ BM HSPCs harvested from Ezh2ﬂ/ﬂ; Mx1-Cre+ were transduced with either MLL-AF9 or AML1-
ETO9a retrovirus and then transplanted into lethally irradiated, WT C57/Bl6 recipients. Following development of leukemia, BM and spleen were harvested and
stored. (2) Secondary leukemias were generated, and following engraftment, Ezh2was excised in situ via intraperitoneal pIpC injections (vs. intraperitoneal PBS
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the minimal effects of GSK343 on the clonogenic function of
normal primary CD34+ hematopoietic stem cells (HSCs; n = 3; Fig.
S3 d). Gene expression differences in GSK343 vs. control-treated
MLL-AF9 tumors in vitro was assessed through RNA sequencing
(RNA-seq; Fig. 2 i and Table S2), with a relatively narrow set of
genes deregulated following Ezh2 inhibition with GSK343 (62 up-
regulated or “derepressed” genes vs. 6 down-regulated). Among
the genes derepressed following Ezh2 inhibition were the cyclin-
dependent kinase inhibitor Cdkn1a (p21Cip1), which has previously
been shown to be up-regulated following genetic loss of Ezh2
(Tanaka et al., 2012), and other genes whose up-regulation may
explain, at least in part, the antileukemic effects, including the
NF-κB inhibitor Nfkbiz. To further assess the value of therapeu-
tically targeting EZH2, particularly in AML1-ETO9a disease, where
we saw the greatest effect in our genetic in vivo experiment, we
developed AML1-ETO9a secondary mouse leukemias and under-
took an in vivo drug trial of EZH2 inhibition, using the compound
EPZ-6438, a clinically relevant EZH2 inhibitor currently in early-
phase trials (NCT01897571). We adopted an oral dosing strategy as
previously described (Knutson et al., 2014) and compared survival
outcomes against mice treated with vehicle control. In consonance
with our in vitro and in vivo genetic disruption experiments in
AML1-ETO9a and preclinical pharmacological observations,
treatment with EPZ-6438 prolonged the survival of AML1-ETO9a
secondary leukemic mice compared with those treated with ve-
hicle control (Fig. 2 j). These data corroborate our genetic studies
and suggest therapeutic potential and a realistic therapeutic
window, identifying EZH2 as a valid target across multiple AML
genotypes.
EZH2 is a tumor suppressor during AML induction, and its
mutation confers a poor prognosis
We next interrogated the role of EZH2 in the preleukemic state
and leukemia induction. Immunophenotyping demonstrated no
signiﬁcant differences in the frequency of HSC, HSPC, and
lineage-negative (Lin−) populations within the c-kit+ compart-
ment (used for the retroviral transduction assays) between
normal Ezh2+/+ and Ezh2−/− genotypes. Moreover, serial replat-
ing if anything was less robust in Ezh2−/− HSPC (Fig. S4 a). In
vitro serial replating assays showed no difference in the clono-
genic output or serial replating potential between Ezh2−/− and
Ezh2+/+ HSPCs transformed with MLL-AF9 or AML1-ETO9a, in
contrast to our maintenance experiments, where we excised
Ezh2 in an already established malignancy (Fig. S4, b and c). We
next generated primary MLL-AF9 or AML1-ETO9a leukemias in
recipient mice using transformation of Ezh2−/− HSPCs and
compared survival and phenotype to Ezh2+/+ leukemias gener-
ated by the same oncogenes (Fig. 3 a). Remarkably, and dia-
metrically opposite to its role in disease maintenance, we
observed that Ezh2 loss signiﬁcantly accelerated the develop-
ment of phenotypically identicalMLL-AF9 and AML1-ETO9a AML
(Fig. 3, b–d; and Fig. S4, d–i). These data demonstrate that Ezh2
functions as a tumor suppressor during AML induction and that
its role is highly context speciﬁc during AML evolution. To
further explore the role of EZH2mutations in human disease, we
extended our analysis into a large cohort of AML patient samples
(n = 2,434) from the National Cancer Research Institute (NCRI)
AML studies (AML14, AML15, AML16, AML17, and LI1). Muta-
tions in EZH2, all of which were predicted loss-of-function
mutations, were detected in 107 patients (∼5%), a ﬁnding in
keeping with previous series (Ley et al., 2013; Papaemmanuil
et al., 2016; Saygin et al., 2018). Using the variant allele fre-
quency to infer clonal structure, in the majority of patients, the
mutations occurred within the dominant clone, with a median
variant allele frequency of 0.385 (Fig. 4 a). As EZH2 mutations
are predominantly hemizygous, these data infer that the muta-
tions occur as early events within the evolution of multiple
leukemias, an observation that strongly corroborates our ex-
perimental data. We further assessed the prognostic signiﬁcance
of EZH2 mutations, correlating the presence of a mutation with
disease outcomes. Across the entire cohort, we could demon-
strate that mutation of EZH2 was associated with a statistically
signiﬁcant decrease in overall survival (OS; 5-yr predicted 31%
EZH2 WT vs. 22% EZH2 mutant; hazard ratio [HR], 1.5; conﬁ-
dence interval [CI], 1.15–1.96; P = 0.0028; Fig. 4 b). However,
EZH2 mutations have been previously documented to occur in
older patients and those with secondary AML or “MDS-like”
AML, subgroups associated with a poorer survival and less
likely to receive intensive therapy (Ernst et al., 2010; Nikoloski
et al., 2010; Lindsley et al., 2015; Saygin et al., 2018). To offset
these potentially confounding variables, we assessed the impact
of mutation in a single AML genotype with signiﬁcant co-
occurrence with EZH2, the chromosomal translocation t(8;21)
subgroup that rearranges the AML1 and ETO genes. Not only
is this subgroup immediately relevant to our experimental
data, it is also predominantly associated with younger age at
presentation and a highly favorable outcome (Grimwade et al.,
1998, 2010; Byrd et al., 2002; Schlenk et al., 2004; Marcucci
et al., 2005). However, as the numbers of patients with co-
occurrence of the AML1-ETO rearrangement and EZH2 muta-
tion in our study were small (n = 7), we combined our series with
another series of 38 patients with t(8;21), 5 of whom also had
co-occurrence of EZH2 mutations, available from a published da-
taset (Faber et al., 2016). Although still limited by small numbers,
our observation across all samples was replicated in this highly
speciﬁc group, with EZH2-mutated patients demonstrating a
similarly unfavorable prognosis (5-yr predicted survival rate,
74 vs. 56%), with an adverse HR for OS (HR, 3.94; CI, 1.00–1.55)
and a strong trend for a lower survival advantage by log-rank
analysis (P = 0.0503; Fig. 4 c). Taken all together, these data,
obtained in large numbers of primary patient samples, cor-
roborate our experimental ﬁndings on the tumor-suppressive
as control). (e) Kaplan–Meier graph demonstrating signiﬁcantly increased survival for Ezh2 excised MLL-AF9 secondary leukemias (n = 12 animals) following
administration of pIpC over PBS-treated Ezh2ﬂ/ﬂMLL-AF9 secondary leukemias (n = 12 animals, log-rank [Mantel–Cox] test P = 0.0163). (f) Kaplan–Meier graph
demonstrating signiﬁcantly increased survival of Ezh2 excised AML1-ETO9a secondary leukemias (n = 9 animals) following administration of pIpC- over PBS-
treated Ezh2ﬂ/ﬂ AML1-ETO9a secondary leukemias (n = 9 animals, log-rank [Mantel–Cox] test P = 0.0011). *, P < 0.05; **, P < 0.01. All error bars are ± SEM.
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Figure 2. Ezh2/EZH2 is a viable therapeutic target across multiple AML genotypes and in primary AML samples. (a) Representative cell proliferation
assay plot demonstrating Ezh2+/+; MLL-AF9 tumor splenocytes cultured in liquid medium exhibit sensitivity to the EZH2 inhibitor GSK343 with an IC50 value
of ∼10 µM. (b) Left: Clonogenic assay for Ezh2+/+; MLL-AF9 tumor splenocytes performed in the presence of DMSO (vehicle control) or 10 µM GSK343
(performed in triplicate, P = 0.0003, two-tailed t test). Right: Photomicrographs demonstrating reduction in colony size upon treatment with GSK343 compared
with DMSO (bars, 100 µm). (c) Flow cytometry at 24 h for H3K27me3 and total H3 demonstrates that 10 µMGSK343 signiﬁcantly reduces H3K27me3 over DMSO
treatment in Ezh2+/+; MLL-AF9 tumor splenocytes cultured in liquid medium. (d) Liquid culture growth assay for human AM1-ETO–positive cell line Kasumi-1
over a 12-d time course in the presence of 10 µM GSK343 compared with DMSO (performed in duplicate). (e) 10 µM GSK343 treatment leads to a modest
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role of EZH2 during AML induction and further implicate
mutation of EZH2 as a poor prognostic factor in AML.
Loss of Ezh2 derepresses speciﬁc transcriptional programs
during AML evolution through loss of bivalent promoter status
To identify the oncogenic transcriptional pathways repressed by
Ezh2 and the mechanisms that facilitate accelerated transfor-
mation following its loss, we performed differential global gene
expression analysis using RNA-seq in Ezh2+/+ and Ezh2−/− non-
transformed (“premalignant”) Lin− HSPCs (Fig. 5 a), comparing
this to similar datasets generated in Ezh2+/+ and Ezh2−/− AML1-
ETO9a andMLL-AF9 leukemias (Fig. 5, b and c). Gene expression
changes were modest and, as anticipated, Ezh2 loss led to a
greater number of genes up-regulated (derepressed) rather than
down-regulated across all three conditions (premalignant, 733
up/69 down; AML1-ETO9a, 540 up/81 down; and MLL-AF9, 496
up/352 down; Tables S3, S4, and S5). Comparing the de-
repressed candidate genes in each condition, within the over-
lapping genes (Fig. 5 a), a few select candidate genes were
up-regulated across multiple conditions, notably Plag1 (common
to all), a transcription factor with known oncogenic roles in
CBFB-MYH11 murine leukemias (Castilla et al., 2004; Landrette
et al., 2005), and the well-characterized oncogenic RNA-binding
protein Lin28b (common to premalignant and MLL-AF9 com-
parisons), which has also been demonstrated to play a role in the
acceleration of JAK2-V617F–driven myeloﬁbrosis following Ezh2
loss (Shimizu et al., 2016). To further explain the contradictory
and opposite effects of Ezh2 loss during AML induction and
maintenance, we compared genes de-repressed in established
MLL-AF9 leukemias following pharmacological inhibition of
Ezh2 (62 genes) to genes derepressed during the induction of
Ezh2−/− MLL-AF9 leukemias (Fig. 5 d). Of note, we could only
demonstrate a minimal overlap between these gene sets (11/496
genes, ∼2%) and similarly, when we compared our genes de-
repressed during induction with a published dataset doc-
umenting genes de-repressed following genetic loss of Ezh2
during the maintenance of MLL-AF9 AML, the overlap was also
low (Tanaka et al., 2012; 60/496 genes, ∼12%). Thus, derepres-
sion of different gene programs explains the contrasting phe-
notypic outcomes of Ezh2 loss of function in AML induction and
maintenance and, together with the minimal toxicity of GSK343
in normal CD34+ cells (Fig. S3 d), provides some reassurances
that targeting EZH2 in established AML will be a safe strategy.
Comparing chromatin immunoprecipitation sequencing (ChIP-
seq) analysis in premalignant HSPC from Ezh2+/+ and Ezh2−/−mice,
a large number of regions demonstrated differential H3K27me3
modiﬁcation (4,545 regions with decreased H3K27me3 modiﬁ-
cation and 5 regions increased). These were linked to 2,544
genes and occurred predominantly at intergenic (47%) regions
and intragenic (53%) regions in keeping with enhancer elements
and promoters, with 28% of the intragenic differential regions
occurring at transcriptional start sites. Comparing regions with
loss of H3K27me3 and up-regulation of gene expression, ∼22%
of genes (162/733 including Plag1 and Lin28b) overlapped,
suggesting that loss of Ezh2-mediated methyltransferase ac-
tivity was directly responsible for their up-regulation
(Fig. 5 e). To further interrogate whether Ezh2 loss impacted
mainly promoter or enhancer function, we performed global
differential ChIP-seq in Ezh2+/+ and Ezh2−/− HSPCs for the
typically enhancer-associated histone modiﬁcation H3K27ac
and promoter-associated H3K4me3 histone marks (Tables S6, S7,
and S8). Of note, we found only 27 regions with an increase in
H3K27ac following Ezh2 loss (compared with 897 with decreased
H3K27ac modiﬁcation). However, in the 162 genes where up-
regulated gene expression correlated with H3K27me3 loss, over
half (88/162, 55%) demonstrated H3K27me loss at their promoter
region. The majority of these genes (132/162, 81%; and 75/88, 85%,
respectively) demonstrated bivalent promoters, with their pro-
moters alsomarked byH3K4me3 in Ezh2+/+WTHSPCs.Moreover,
in a small subset of genes (6/88, 7%) that included Plag1 and Lin28b
(Figs. 5 f and S5 a), the H3K4me3 modiﬁcation signal was actually
seen to signiﬁcantly increase following Ezh2 loss. These data
suggest that during AML induction Ezh2 loss does not alter en-
hancer function but results in the resolution of a small number of
bivalent promoters, leading to derepression of their genes and up-
regulation of an oncogenic program.
Plag1 is a speciﬁc downstream mediator of Ezh2 loss
Finally, to functionally validate candidate genes from these
derepressed programs as potential mechanistic effectors of the
accelerated AML induction following Ezh2 loss in vivo, we
generated retroviral constructs for Plag1 and Lin28b. These genes
were overexpressed along with MLL-AF9 in WT Ezh2+/+ HSPCs.
Bulk-transduced populations were transplanted into recipient
mice to generate primary murine leukemias (Fig. S5, b and c)
and determine if coexpression of Plag1 or Lin28b would pheno-
copy Ezh2 loss and accelerate AML onset in comparison with
MLL-AF9 alone. Overexpression of Lin28b in transgenic mice
results in peripheral T cell lymphomas with a relatively lengthy
latency (Beachy et al., 2012), while Plag1 overexpression alone
does not induce disease (Landrette et al., 2005), so neither alone
were predicted to cause AML. The Lin28b+MLL-AF9 transplanted
increase in apoptosis at late time points (96 h) in the Kasumi-1 cell line compared with DMSO (P = 0.037, two-tailed t test, performed in triplicate). (f) Rep-
resentative cell cycle analysis plot at 96 h in Kasumi-1 also demonstrates mild G0/G1 cell cycle arrest following 10 µMGSK343 treatment. (g) Colony assays across
a wide range of AML patient samples (n = 15) demonstrates a signiﬁcant reduction in colony numbers following treatment with 10 µM GSK343 compared with
DMSO. Cases include varying molecular subtypes, with variable karyotypic mutational and prognostic status. (P = 0.01, two-tailed t test). (h) Photomicrographs of
two different human primary AML samples in a clonogenic assay cultured with either DMSO or 10 µM GSK343 (bars, 500 µm). (i) Volcano plot for DMSO- vs.
10 µM GSK343–treated Ezh2+/+; MLL-AF9 tumor splenocytes cultured in liquid medium demonstrating gene expression changes and showing the adjusted
signiﬁcance P value (log10) vs. fold change (log2; n = 2, biological replicates for DMSO and GSK343). Potential candidates that might underlie the antileukemic
effects, Cdkn1a and Nfkbiz, are identiﬁed. (j) Kaplan–Meier graph of survival of secondary transplants of AML1-ETO9a AML generated from Ezh2+/+ mice
comparing EPZ-6438–treated (n = 7) and vehicle control–treated (n = 6; log-rank [Mantel–Cox] test P = 0.0103). *, P < 0.05; **, P < 0.01. All error bars are ± SEM.
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cohort demonstrated no signiﬁcant difference in survival
(Fig. 5 g; P = 0.22). In contrast, Plag1 overexpression with MLL-
AF9 profoundly accelerated the development of leukemia com-
pared with the MLL-AF9 control arm (Fig. 5 g; P < 0.0001).
Strikingly, even within the Plag1/MLL-AF9 transplanted mice,
we observed a marked expansion of the dual Plag1/MLL-AF9
(YFP+/mCherry+)–transduced cells over the single MLL-AF9
(YFP+ only)–expressing leukemia cells (from a 1:1 ratio at the
time of transplant to an average of 12:1 at the time of necropsy;
Fig. S5 d) when BM tissues were analyzed (Fig. 5 h), demon-
strating a strong selective advantage for the combination of
MLL-AF9 and Plag1. These data identify Plag1 as an oncogene
whose de-repression contributes to EZH2-mutated AML. More-
over, neither expression of Plag1 nor Lin28b was signiﬁcantly
altered following GSK343 treatment of MLL-AF9 tumors, re-
inforcing the concept of disparity between transcriptional pro-
grams repressed by Ezh2 that are responsible for early tumor
suppression and later maintenance of these leukemias.
Discussion
The methyltransferase Ezh2 has pleiotropic effects during de-
velopment and homeostasis and in pathological conditions such
as cancer (Cao et al., 2002; Kuzmichev et al., 2002; Varambally
Figure 3. Ezh2 functions as a tumor suppressor during the induction of disparate subtypes of AML in vivo. (a) Schema of the in vivo experiments.
Ezh2ﬂ/ﬂ; WT or Ezh2ﬂ/ﬂ; Mx1-Cre+ mice were treated with pIpC to induce Ezh2 deletion in Mx1-Cre–expressing mice before retroviral transduction with either
MLL-AF9 or AML1-ETO9a retrovirus followed by transplantation into lethally irradiated WT C57/Bl6 recipient mice. (b) Kaplan–Meier graph demonstrating
signiﬁcantly increased survival for Ezh2+/+; MLL-AF9 (WT) primary leukemias (n = 8 animals) vs. Ezh2−/−; MLL-AF9 primary leukemias (n = 8 animals, log-rank
[Mantel–Cox] test P = 0.0341). (c) Kaplan–Meier graph demonstrating signiﬁcantly increased survival for Ezh2+/+; AML1-ETO9a (WT) primary leukemias (n = 6
animals) vs. Ezh2−/−; AML1-ETO9a primary leukemias (n = 8 animals, log-rank [Mantel–Cox] test P = 0.0004). (d) Histopathology of spleen (left) and BM (right)
taken at necropsy in Ezh2+/+ vs. Ezh2−/− AML1-ETO9a murine primary leukemias. Both samples show obvious and similar degrees of leukemic inﬁltration with
large primitive blast cells that demonstrated a myeloid phenotype on ﬂow cytometry, with no macroscopic or microscopic phenotypic difference demonstrated
between the leukemias of either genotype (bars, 100 µm). *, P < 0.05; ***, P < 0.001.
Basheer et al. Journal of Experimental Medicine 972
Contrasting, stage-dependent roles of EZH2 in AML https://doi.org/10.1084/jem.20181276
et al., 2002; Kleer et al., 2003; Francis et al., 2004; Kamminga
et al., 2006; Barski et al., 2007; Wagener et al., 2008;
Ezhkova et al., 2009; Simon and Kingston, 2013). Our ﬁndings
uncover novel and dramatically opposing functions of Ezh2
during AML evolution that are dependent upon the phase of
disease, with Ezh2 functioning as a tumor suppressor in AML
induction and as a facilitator of disease in established AML.
These apparently contradictory phenotypes can be explained by
derepression of almost mutually exclusive transcriptional path-
ways normally repressed by Ezh2-mediated H3K27 methylation
in each phase. These data highlight the impact of cellular
context on the function of Ezh2, the PRC2 complex, and epi-
genetic regulators in general. To our knowledge, this is the ﬁrst
description of an epigenetic regulator having both tumor-
suppressive and oncogenic function in different phases of the
same cancer. In addition, our work further validates EZH2 as a
therapeutic target in MLL-rearranged leukemias and, from
the use of another mouse model and a number of different AML
patient samples, extends this therapeutic potential more gen-
erally across other AML genotypes. However, loss of EZH2
protein has also been demonstrated to up-regulate HOX gene
expression and to mediate resistance to certain targeted and
chemotherapy agents (Go¨llner et al., 2017). Critically, our de-
tailed analysis demonstrates that Ezh2 functions only as a
tumor suppressor during leukemia induction and that its cat-
alytic inhibition does not up-regulate HOX genes during AML
maintenance (Table S2). These data, along with the observation
that in MDS, Ezh2 loss facilitates disease occurrence but retards
progression to AML (Sashida et al., 2014), provide some re-
assurances that targeting EZH2 is a safe strategy in established
disease.
Our ﬁndings also suggest that EZH2 mutations confer a poor
prognosis on AML patients, with this clinical observation cor-
roborating our experimental ﬁndings during disease induction.
Further supporting our ﬁndings, a similar poor prognosis has
previously been described for patients with EZH2mutations and
the related myeloid malignancies MPN and MDS (Guglielmelli
et al., 2011; Bejar et al., 2012), and recent efforts to reﬁne
prognostic groups within AML (Papaemmanuil et al., 2016) have
identiﬁed the chromatin and spliceosome group, in which EZH2
mutations are grouped, as one of the groups with the poorest
survival. However, as we have alluded to, EZH2 mutations
Figure 4. EZH2 mutations may occur as early events in human AML and confer poor prognostic outcomes across unselected AML and within the
t(8;21)-rearranged human AML subtype. Analysis of a large AML patient cohort (n = 2,434) demonstrated 120 patients to have EZH2 loss-of-function
mutations. (a) These patients demonstrated a high variant allele frequency (median 38.5%) by violin plot in keeping with EZH2 mutation occurring early in
disease evolution. (b) OS was available for 2,421 patients. For EZH2-mutated AML patients (n = 106), OS is signiﬁcantly reduced compared with EZH2WT (n =
2,315; OS, 5-yr predicted survival rate, 31% EZH2 WT vs. 22% EZH2 mutant; HR, 1.5; CI, 1.15–1.96; log-rank [Mantel–Cox] test P = 0.0028). (c) OS for EZH2-
mutated human t(8;21) AML patients (n = 12) is reduced compared with EZH2WT (n = 127; OS, 5-yr predicted survival rate, 74% EZH2WT vs. 56% EZH2mutant;
HR, 3.94; CI, 1.15-1.96; log-rank [Mantel–Cox] test P = 0.0503). **, P < 0.01.
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Figure 5. Integrated genomic analysis providesmechanistic insights into Ezh2’s tumor-suppressive function in AML induction at both chromatin and
molecular levels and identiﬁes pleiomorphic adenoma gene 1 (Plag1) as a potent downstreammechanistic effector of Ezh2 loss. (a) Left: Volcano plot
for Ezh2+/+ vs. Ezh2−/− normal murine c-kit+ BM HSPCs demonstrating gene expression changes and showing the adjusted signiﬁcance P value (log10) vs. fold
change (log2; n = 2, biological replicates for Ezh2+/+ and Ezh2−/−). Right: Venn diagram showing overlap of up-regulated genes following Ezh2 loss in normal
murine c-kit+ BM HSPCs (n = 733) compared with genes differentially up-regulated in Ezh2−/−MLL-AF9 murine leukemias (n = 496) and genes differentially up-
regulated in Ezh2−/− AML1-ETO9a murine leukemias (n = 540). (b) Volcano plot for Ezh2+/+ vs. Ezh2−/− AML1-ETO9a murine leukemias demonstrating gene
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cosegregate with other poor-risk characteristics, such as patient
age and an increased likelihood of antecedent myeloid malig-
nancy such as MPN or MDS. Our studies within a single good-
risk genotype, the t(8;21) subgroup, suggest that EZH2 mutation
is an independent poor-risk characteristic in AML; however,
further studies are necessary to determine its exact role as a
prognostic factor.
The PRC2 complex, with Ezh2 as its catalytic component, is
known to repress gene expression through H3K27me3 mediated
effects on both proximal promoter and distal enhancer cis-
regulatory elements. Although we have demonstrated that loss
of H3K27me3 following loss of Ezh2 occurs at both, the majority
of regions with H3K27me3 loss occur at distal and intragenic
enhancer regions. Of note, however, our data suggest that loss of
Ezh2 mediates its tumor-suppressive effects predominantly
through alterations of H3K27me3 at promoters rather than en-
hancers. During disease induction, over half of the derepressed
genes lose H3K27me3 at their promoters. In contrast, only 30
derepressed genes lost H3K27me3 at enhancer elements.
Moreover, global analysis of the reciprocal activation mark,
H3K27Ac, demonstrated only minimal changes, and no up-
regulated gene demonstrated coordinated loss of H3K27me3
and gain of H3K27Ac at an enhancer element. These ﬁndings in
AML are in contrast to the changes described in MPN models,
where Ezh2 loss accelerated Jak2V617F-driven myeloﬁbrosis
(Shimizu et al., 2016; Yang et al., 2016). These highlight an
“epigenetic switch,” where loss of H3K27me3 is accompanied by
an increase in H3K27Ac following Ezh2 loss and leukemia-
initiating cells from the Ezh2−/−/Jak2V617F mice showed sensi-
tivity to BET inhibitors, targeting gene expression related to
altered H3K27Ac (Sashida et al., 2016). However, our data
demonstrate that in AML, Ezh2maintains H3K27me3 at bivalent
promoters to repress speciﬁc oncogenes during disease induc-
tion. Our data are in keeping with the effects of normal and
mutant Ezh2 during lymphoid development and lymphoma-
genesis (Be´guelin et al., 2013). During normal B cell develop-
ment, Ezh2 is an absolute requirement for the germinal center
reaction, where it transiently halts terminal B cell development
by maintaining the repressive H3K27me3 mark at a subset of
bivalent promoters for genes involved in terminal B cell differ-
entiation, such as IRF4 and PRDM1. In mice overexpressing the
activating mutation Ezh2Y641F, the increased catalytic activity of
this mutation leads to increased H3K27me3 deposition and
permanent silencing at these genes, facilitating lymphoma-
genesis by preventing further differentiation and perpetuating
the germinal center reaction (Be´guelin et al., 2013). Similarly, in
the differentiation of invariant natural killer T cells (iNKTs), the
balance between Ezh2-mediated methylation and Utx/Kdm6a–
mediated demethylation of H3K27 at the bivalent promoter of
the iNKTmaster regulator Plzf determines the expression of Plzf
and the emergence of iNKTs (Beyaz et al., 2017).
Thus, our data reveal that the tumor-suppressive functions of
Ezh2 are to maintain repression of a small number of oncogenes,
including Plag1 and potentially Lin28b, which, upon derepres-
sion, contribute to more rapid AML development (Fig. 5 i).
Lin28b is an RNA-binding protein and master regulator of mi-
croRNA function, including the Let7 family of microRNAs
(Viswanathan et al., 2008; Piskounova et al., 2011). Lin28b-
mediated repression of Let7 leads to the subsequent over-
expression of a number of oncogenic targets, including Hmga2,
Igf2bp1, Ras, and Myc, dependent upon the cellular context
(Balzeau et al., 2017). The Lin28b–let7–Hmga2 axis has also been
demonstrated to regulate fetal HSCs, and Lin28bwas proposed as
a master regulator of developmentally timed changes in HSCs
and to account for their additional proliferative and self-renewal
advantage over their adult counterparts (Copley et al., 2013).
Plag1, the pleiomorphic adenoma gene 1, encodes a zinc-ﬁnger
transcription factor, ﬁrst described as a gene fusion partner in
salivary gland pleiomorphic adenomas (Kas et al., 1997). Plag1
and its homologue, Plagl2, have also previously been implicated
in leukemia, being observed as candidate cooperating oncogenes
in a retroviral insertion screen with the CBFβ-MYH11 product of
the inv16 gene rearrangement (Castilla et al., 2004). Retroviral
overexpression individually with CBFβ-MYH11 conﬁrmed each
of them to be a cooperating oncogene, and this study further
demonstrated their overexpression in ∼20% of human AML
samples (Landrette et al., 2005). Of note, similarly to the
Lin28b–let7 axis, Plag1 also activates the IGF2 mitogenic sig-
naling pathway (Van Dyck et al., 2007). Additionally, by linking
these candidates, we could also demonstrate an up-regulation of
Plag1 expression in Lin28b-overexpressing HSPCs (Fig. S5 b), and
recurrent rearrangements of the downstream target of the
expression changes and showing the adjusted signiﬁcance P value (log10) vs. fold change (log2; n = 2, biological replicates for Ezh2+/+ and Ezh2−/−). (c) Volcano
plot for Ezh2+/+ vs. Ezh2−/− MLL-AF9 murine leukemias demonstrating gene expression changes and showing the adjusted signiﬁcance P value (log10) vs. fold
change (log2; n = 2, biological replicates for Ezh2+/+ and Ezh2−/−). (d) Venn diagram of genes up-regulated following Ezh2 loss during MLL-AF9 induction (n =
496) with genes up-regulated following Ezh2 inhibition in MLL-AF9 maintenance (n = 62) demonstrates only minimal overlap. (e) Overlap between down-
regulated H3K27me3 peaks (n = 4,545, relating to 2,544 genes) and up-regulated genes (n = 733) following Ezh2 loss in normal murine c-kit+ BM HSPCs
demonstrates ∼20% of genes up-regulated are due to loss of the H3K27me3 repressive mark at chromatin (hypergeometric test P = 1.187 × 10−18). (f) ChIP-seq
analysis of H3K27me3 and H3K4me3 chromatin marks reveals resolution of conﬂicting histone marks H3K27me3 and H3K4me3 at the bivalent promoter region
in favor of gene activation for the oncogene Plag1 in WTmurine Lin− BMHSPCs following Ezh2 loss, explaining its increased expression. (g) Kaplan–Meier graph
demonstrating signiﬁcantly decreased survival for MLL-AF9/Plag1–overexpressing primary leukemias (n = 8 animals, log-rank [Mantel–Cox] test P < 0.0001)
compared with MLL-AF9 primary leukemias (n = 8 animals, control). MLL-AF9/Lin28b–overexpressing primary leukemias trend toward accelerated leukemia
induction (although NS). (h) Expansion of dual YFP (MLL-AF9)– and mCherry (Plag1)–expressing BM cells compared with single YFP (MLL-AF9)–expressing BM
cells of terminalMLL-AF9/Plag1 leukemias as assessed by ﬂow cytometry (n = 7 leukemias in each arm shown; P < 0.0001, two-tailed t test). (i)Model (see text
also). During normal hematopoiesis (EZH2+/+), EZH2 prevents the aberrant expression of oncogenes such as Plag1 (shown) and Lin28b through maintenance of
H3K27me3 and a bivalent state at their gene promoters (top). However, following EZH2 loss of function (EZH2−/−), loss of methyltransferase activity leads to a
decrease in the H3K27me3 modiﬁcation at the promoters of oncogenes such as Plag1 and Lin28b and resolution of the bivalent state toward gene activation,
accelerating AML induction and conferring a poor prognosis. ***, P < 0.001. All error bars are ± SEM.
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Lin28b–let7 axis, HMGA2, also occur in salivary gland adenomas,
further suggesting a degree of redundancy in the pathways ac-
tivated by Lin28b and Plag1. Of note, Lin28b, but not Plag1, was
also demonstrated to be up-regulated following loss of Ezh2
during the accelerated development of Jak2V617F-mediated
myeloﬁbrosis (Sashida et al., 2016; Shimizu et al., 2016). Taken
altogether, our study conﬁrms that Lin28b appears to be a com-
mon oncogenic target across multiple myeloid malignancies and
Plag1 a speciﬁc target in AML up-regulated following Ezh2 loss.
These data also suggest that common pathway activation, such as
IGF2 signaling, at least in part, underpins the accelerated leu-
kemogenesis observed following their derepression (Fig. S5 e).
In summary our data demonstrate the context-dependent
roles of epigenetic regulators during tumor evolution. Speciﬁ-
cally, for loss of Ezh2, we identify chromatin-based mechanisms
and candidate genes whose derepression accelerates AML
generation, and we demonstrate that its mutation confers a
poor prognosis on AML patients. In contrast, during AML
maintenance, we functionally demonstrate that WT Ezh2 plays
an oncogenic role and show that it can be effectively thera-
peutically targeted to up-regulate an entirely different and
tumor-suppressive program. This compartmentalized func-
tion suggests that it can be safely targeted across multiple
AML genotypes.
Materials and methods
Mice
C57/BL6 strain mice engineered from the Wellcome Trust
Sanger Institute pipeline (Skarnes et al., 2011) to have a loxp site
ﬂanking exon 9 of the Ezh2 sequence in a homozygous fashion
(Ezh2ﬂ/ﬂ) were bred in-house. Successive breedings between
these and mice heterozygous forMx1-Cre recombinase generated
litters of Ezh2ﬂ/ﬂ; Mx1-Cre WT (Ezh2ﬂ/ﬂ; WT) or Ezh2ﬂ/ﬂ; Mx1-Cre
heterozygous (Ezh2ﬂ/ﬂ; Cre+) mice. To induce Cre-mediated re-
combination, 6-wk-old Ezh2ﬂ/ﬂ; Cre+ and Ezh2ﬂ/ﬂ; WT mice were
administered ﬁve doses of pIpC (300 µg per dose; Sigma) via
intraperitoneal injection on alternate days over 10 d. All ex-
periments were performed using littermates unselected for
gender but age matched from date of birth and timing of pIpC
administration. Peripheral blood was collected and counted as
previously described (Chan et al., 2011). Excision efﬁciency was
characterized by quantitative PCR (qPCR) of genomic DNA ex-
tracted from whole blood or BM. All mice were housed in a
speciﬁc pathogen–free animal facility allowing unrestricted ac-
cess to food and water, and all experiments were conducted
under UK Home Ofﬁce regulations under a UK Home Ofﬁce
project license. This research has been regulated under the
Animals (Scientiﬁc Procedures) Act 1986 Amendment Regu-
lations 2012 following ethical review by the University of
Cambridge Animal Welfare and Ethical Review Body.
Isolation of murine cell populations
For the transplantation experiments, mice were euthanized
humanely and both femurs and tibias harvested. These were
ﬂushed with sterile PBS, yielding BM cells that were then ﬁl-
tered through a 70-µm EASYstrainer (Greiner). RBCs were lysed
using RBC lysis buffer (5 PRIME). For the serial replating and
transplantation experiments, BM cells from Ezh2ﬂ/ﬂ; WT or
Ezh2ﬂ/ﬂ; Cre+ were selected for cell-surface c-kit expression us-
ing CD117 MicroBeads (Miltenyi Biotec) according to the man-
ufacturer’s protocol. For the Lin28b/Plag1 in vivo validation
experiments, c-kit–positive BM cells from 8–12-wk-old C57/BL6
WT mice were isolated in the same way.
For the ChIP-seq experiments, Lin− HSPCs from whole mu-
rine BM were isolated using a Lineage Cell depletion kit (Mil-
tenyi Biotec) as per the manufacturer’s protocol.
Mouse transplantation experiments
For the induction experiments, retrovirally transduced Ezh2ﬂ/ﬂ;
WT or Ezh2ﬂ/ﬂ; Cre+ BM cells (both pretreated with pIpC to in-
duce Ezh2 deletion in the Cre+ arm) were generated, yielding
Ezh2+/+ or Ezh2−/− states respectively. After assessment of
transduction efﬁciency, 0.2–1.5 × 106 bulk BM cells from each
arm (containing an equal number of positively transduced cells)
were transplanted into age-matched lethally irradiated (two
doses of 5.5 Gy each) C57/BL6 WT recipient mice via tail vein
injection, generating Ezh2+/+ and Ezh2−/− leukemia arms for each
oncogene. Similarly, for the maintenance experiments, to gen-
erate primary leukemias, retrovirally transduced Ezh2ﬂ/ﬂ; Cre+
BM cells (obtained from 8–12-wk-old mice) were transplanted
via tail vein injection into lethally irradiated (two doses of 5.5 Gy
each) C57/BL6 WT recipient mice. For secondary leukemias, 106
bulk splenocytes harvested from primary leukemic mice were
transplanted into age-matched lethally irradiated C57/BL6 WT
recipient mice via tail vein injection, and pIpC or an equal vol-
ume of PBS (control) was administered intraperitoneally fol-
lowing engraftment.
Histopathology
All tissues were ﬁxed, embedded, and section as described
previously (Giotopoulos et al., 2015).
Western blotting
Western blotting was performed using 12% SDS-PAGE gels and
standard protocols. The antibodies used were anti-Tri-Methyl-
Histone H3 (9733; Cell Signaling Technology) and anti-Tubulin
(44928; Abcam). Secondary antibodies were IRDye 680RD and
IRDye 800CW (LI-COR Biosciences). An Odyssey Infrared
Imaging system (LI-COR Biosciences) was used to scan the
immunoblots.
Serial replating assays
Normal or immortalized mouse BM cells were plated at con-
centrations of 3.3–5 × 104/plate (in duplicate) using MethoCult
GF M3434 (STEMCELL Technologies) methylcellulose medium
to assess myeloid potential. Colonies were scored manually
(and/or using an automated reader, STEMvision; STEMCELL
Technologies), total cell numbers were measured at 7 d, and
equal numbers of cells were replated using the same conditions.
Retroviral transduction assays
For virus production, TransIT-LT1 transfection reagent
(Mirus) was used to transfect the individual retroviral vectors
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MSCV-MLL-AF9-IRES-YFP, MSCV-AML1-ETO9a-IRES-GFP, MSCV-
Lin28b-IRES-mCherry, MSCV-Plag1-IRES-mCherry, p-babe-puro,
or p-babe-Cre-puro and the psiEco packaging plasmid in a 1:1 ratio
into 293T cells according to the manufacturer’s protocol. Super-
natant was harvested 48 and 72 h after transfection. One million
cells were resuspended into 1 ml retroviral supernatant supple-
mented with mIL-3, IL-6, and murine stem cell factor cytokines
(ﬁnal concentrations of 10 ng/ml, 10 ng/ml, and 100 ng/ml re-
spectively; Peprotech) and polybrene to a ﬁnal concentration of
8 ng/µl. Cells were spinoculated with retroviruses as previously
described (Giotopoulos et al., 2016).
EPZ6438 in vivo dosing experiments
AML1-ETO9a AML murine leukemias were injected intrave-
nously into lethally irradiated C57BL/6 (CD45.1) congenic re-
cipients (2 million AML cells and 300,000 CD45.1 BM helper
cells/mouse). Upon disease dissemination, EPZ-6438 (Insight
Biotechnology) or vehicle (1% DMSO, 0.5% carboxymethylcel-
lulose sodium salt, and 0.1% Tween-80 in water) was adminis-
tered daily by oral gavage (160 mg/kg).
Cell culture and inhibitor assays
Kasumi-1, KG1, K562, MOLM-13, and MV411 cell lines were grown
in RPMI-1640 medium supplemented with FBS and penicillin/
streptomycin (10–20% and 1% ﬁnal concentration, respectively;
Sigma-Aldrich). Splenocytes from leukemic MLL-AF9 mice were
passaged in X-Vivo 20 culture medium (Lonza) supplemented with
mIL-3, IL-6, and murine stem cell factor cytokines (ﬁnal concen-
trations of 10 ng/ml, 10 ng/ml, and 50 ng/ml respectively; Pepro-
tech). Human AML cell lines, mouse tumors, and human primary
AML cells were plated in duplicate in methylcellulose medium. For
AML cell lines, 30,000 cells per plate were used. For murine MLL-
AF9 tumors, 50,000 splenocytes per plate were used. For primary
AML samples, 50–80,000 cells per plate were used. For AML cell
lines and primary AML samples, MethoCult H4435 (STEMCELL
Technologies) was used, and formurine cells,MethoCult GFM3434
was used in the presence of DMSO or the small-molecule EZH2
inhibitor GSK343 (10 µM). Colonies were scored at 7–12 d.
Cell proliferation and liquid culture assays
Kasumi-1 cells cultured in the conditions detailed above were
plated at concentrations of 0.5 × 106/ml into 12-well plates, to
which DMSO or GSK343 (10 µM) was added, mixed, and incu-
bated. Cells were counted using a CASY Counter (Scha¨rfe Sys-
tem GmbH) at 72 h, resuspended in fresh media, and returned to
the original concentration. This was repeated at 144, 216, and
288 h, and total cell numbers were counted. The CellTiter 96
AQueous One Solution Cell Proliferation Assay (Promega) was
used to assay the antiproliferative and cytotoxic effects of
GSK343 against human AML cell lines and mouse leukemic cells
as per the manufacturer’s protocol. Proliferation curves and IC50
values were generated using Prism statistical software.
Human primary AML sample collection, processing,
and sequencing
Peripheral blood/BM samples were collected from newly diag-
nosed/relapsed patients with AML into cytogenetic media
(RPMI supplemented with Hepes, lithium heparin, and genta-
micin). This was part of the Causes of Clonal Blood Cell Disorders
study (Department of Haematology, University of Cambridge)
approved by the Cambridge and Eastern Region Ethics Com-
mittee. Patients gave written informed consent, and research
was performed in accordance with the Declaration of Helsinki.
All samples were anonymized and identiﬁable only by a tissue
bank code. The mononuclear fraction was obtained following a
1:1 dilution in PBS and layering onto 1:1 volume of Lymphoprep
(Axis-Shield). Samples were centrifuged for 45 min at 1,400
rpm, and the mononuclear fraction was carefully removed using
a 1-ml pipette. After washing in MACS buffer (500 ml PBS
without Ca/Mg, 2.5 g BSA, and 2 ml of 0.5 M EDTA, ﬁlter ster-
ilized), cells were counted for use. For assessment of EZH2
mutation status, DNA from AML samples from the UK NCRI AML
study group trials AML 14 (ISRCTN62207270/ClinicalTrials.gov
number NCT00005823), AML15 (ISRCTN17161961/EudraCT num-
ber 2005–001149-40), AML16 (ISRCTN 11036523/ClinicalTrials.gov
number NCT00454480), AML17 (ISRCTN31682779/EudraCT
number 2013–002730-21), AML18 and LI1 (ISRCTN40571019) were
sequenced using solution-based capture hybridization and next
generation sequencing using a captured based panel of 126 genes.
Variants in EZH2 were called using established in house algorithms
and manual variant annotation was conducted to retain putative
oncogenic variants as previously described (Papaemmanuil et al.,
2016). The average depth over the EZH2 locus was 230× and for the
reported mutations variant allele fractions were corrected for local
copy-number changes as well as focal regions of homozygosity.
Clinical outcome data were available for 2,421 cases in our study. In
addition to the case studies as part of the UK NCRI trials, mutation
and outcome datawere available from a further published dataset of
38 AML1-ETO patients that contained ﬁve patients with EZH2
mutations and AML1-ETO rearrangements (Faber et al., 2016).
Flow cytometry
Single-cell suspensions of BM or spleen were prepared as pre-
viously described (Chan et al., 2011). All analyses considered
only 7-AAD− (BD) populations. Annexin V (APC conjugated; BD)
and 7-AAD were used in cell viability assays according to the
manufacturer’s protocol. For cell cycle analysis, cells were
washed in PBS, ﬁxed in 70% ethanol in PBS and resuspended in
50 µg/ml propidium iodide with 0.1 mg/ml RNase then incu-
bated at 37°C for 30 min. To assess H3K27me3 status following
Ezh2 inhibitionwith GSK343, 8 × 106 Ezh2ﬂ/ﬂ; WTMLL-AF9 AML
splenocytes from two tumors were passaged (in duplicate) in
X-Vivo 20 media at 0.5 × 106/ml concentrations. At 0 h, DMSO
and GSK343 (10 µM) were added to each MLL-AF9 tumor. At 24,
48, and 72 h, 106 cells from each condition were resuspended in
BD Cytoﬁx/Cytoperm solution (BD Biosciences) and incubated
and washed with 10× BD Perm/Wash cell permeabilizing buffer
(BD Biosciences) as per the manufacturer’s protocol. Cells were
then resuspended in BD Perm/Wash buffer containing either
H3K27me3–Alexa Fluor 647–conjugated antibody (1:100 dilution;
Abcam) or Histone H3–Paciﬁc Blue–conjugated antibody (1:50
dilution; Cell Signaling Technology). At each time point, re-
maining cells were washed and returned to 0.5 × 106/ml con-
centration with fresh media. Unstained cells were used to gate
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live cells. GFP/YFP and mCherry were integrated into several
DNA constructs used across retroviral transduction and over-
expression experiments. Assessment of these markers by ﬂow
cytometry across MLL-AF9 (YFP) or AML1-ETO9a (GFP)–
transformed murine c-kit+ BM cells, mononuclear cells obtained
from blood samples of mice with these leukemias, and tissues
isolated from terminal leukemic mice allowed for an estimation
of the percentage of transformed cells or leukemic burden to be
made. The mCherry marker was used in the MSCV-IRES-
mCherry constructs that candidate genes Lin28b and Plag1 were
cloned into for functional assessments of expression. Flow cy-
tometry was performed on a BD LSRFortessa cell analyzer, and
all data were analyzed with FlowJo software (Tree Star).
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated using an AllPrep DNA/RNA Mini kit
(QIAGEN). cDNA was then prepared from 0.5 µg RNA using the
SuperScript III Reverse transcription Kit (Invitrogen). qRT-PCR
was performed on diluted cDNA (1:10 in water) using Brilliant III
Ultra-Fast QPCRMaster Mix (Agilent) and gene-speciﬁc primers
(Sigma-Aldrich) on an MX3000p qPCR system (Agilent) and
standard cycling setup. The following primer sequences were
determined from Primer3 (http://primer3.ut.ee): Lin28b for-
ward, 59-ATGGCACTTCTTTGGCTGAG-39; Lin28b reverse, 59-
ATAGGTGGAGACGGCAGGAT-39; Plag1 forward, 59-GACAAG
GCCTTTAACAGTGTTG-39; and Plag1 reverse, 59-TCAGGAGAG
TGAGTAGCCATG-39.
RNA-seq
Total RNA was extracted from Lin− BM cells isolated from 6-wk-
old Ezh2ﬂ/ﬂ; Cre+ and Ezh2ﬂ/ﬂ; WT mice after pIpC treatment
using an AllPrep DNA/RNA Mini Kit as per the manufacturer’s
protocol. RNA was also extracted from unfractionated BM of
MLL-AF9 and AML1-ETO9a malignant Ezh2+/+ and Ezh2−/− mice
and from malignant splenocytes from Ezh2+/+ MLL-AF9 mice
propagated and cultured in vitro 24 h after DMSO and GSK343
treatment. RNA was quantiﬁed using a NanoDrop 1000 Spec-
trophotometer (Thermo Scientiﬁc). For each experiment, 5 µg
RNA was used for library preparation using a Rapid Directional
RNA-Seq Kit (NEXTﬂex). Library quality was checked, and
barcoded libraries were pooled together and sequenced at the
Cancer Research UK (CRUK) Cambridge Institute genomics core.
Paired end RNA-seq reads were quality ﬁltered and mapped
using STAR3 against the mouse genome (mm10). Read counts
were quantiﬁed with HTSeq (Anders et al., 2015) and differen-
tial expression analysis was performed with these counts using
Bioconductor package DESeq2 (Love et al., 2014). Features with
adjusted P value <0.05 and absolute logarithmic (base 2) fold
change >0.5 were considered as having signiﬁcantly altered
expression.
ChIP-seq
Chromatin immunoprecipitation was performed onmurine Lin−
BM HSPCs as previously described (Horton et al., 2017). Cells
were cross-linked with 1% formaldehyde for 5 min for histone
markers (H3K27me3, H3K27Ac, and H3K4me3; Millipore, Ab-
cam, and Diagenode, respectively). ChIP-seq library preparation
of ChIP DNA or input DNA was performed using TruSeq ChIP
Sample Prep Kit (Illumina). KAPA Library Quantiﬁcation kit
(Kapa Biosystems) was used for library DNA quantiﬁcation.
Average library size was determined using an Agilent DNA 1000
Kit (Agilent Technologies) run on a 2100 Bioanalyzer System
(Agilent Technologies). Libraries were then pooled for multi-
plexing for single-read sequencing on an Illumina HiSeq 4000
machine at the Genomics Core, CRUK Cambridge Institute. Ex-
periments were performed in duplicate on biologically inde-
pendent samples.
ChIP-seq data analysis
Adapter sequences were trimmed for all reads and mapped
against the mm10 reference genome using Bowtie2 (Langmead
and Salzberg, 2012). Uniquely mapped reads were retained, and
peaks were called using SICER (Xu et al., 2014) with W200 and
G600 parameters. Peaks in intergenic regions were assigned to
genes if they were within the 100-kb window from the tran-
scriptional start site. Differential binding analysis was per-
formed using DiffBind (Ross-Innes et al., 2012). Overlapping
analysis of peaks was performed using intersectbed from bed-
tools (Quinlan and Hall, 2010). Data were displayed as UCSC
genome browser custom tracks. After peak calling, differentially
bound histone peak lists generated from Ezh2+/+ and Ezh2−/−
conditions were ﬁltered to select all those peaks with a false
discovery rate of <0.01. Features with fold changes >1.5 were
considered to have signiﬁcant differential binding.
Statistical analysis and reproducibility
Unless otherwise stated, all statistical analyses used Student’s
two-tailed t test on raw data. P values ≤0.05 were considered
statistically signiﬁcant. Survival curves were constructed using
the Kaplan–Meier method, and statistical signiﬁcance was cal-
culated using log-rank analysis. The number of independent
experiments and mice in transplantation experiments used to
generate statistically signiﬁcant data are detailed in the relevant
ﬁgure legends.
Data availability
All RNA-seq and ChIP-seq data have been deposited in the Gene
Expression Omnibus database under the accession no.
GSE112724.
Online supplemental material
Fig. S1 shows transduction efﬁciencies and Cre-recombinase
toxicity in Ezh2wt/wt and Ezh2ﬂ/ﬂ MLL-AF9–transformed cell
lines (related to Fig. 1, b–d). Fig. S2 shows disease parameters in
AML1-ETO9a secondary murine leukemias (related to Fig. 1 f).
Fig. S3 shows GSK343 activity against human AML cell lines,
immortalizedmurine cell lines, and primary human CD34+/AML
samples (related to Fig. 2). Fig. S4 shows the HSC and HSPC BM
composition of Ezh2−/− mice, serial replating assays, and disease
parameters for MLL-AF9 and AML1-ETO9a murine leukemias
for the EZH2 is a tumor suppressor during AML induction...
section (related to Fig. 3). Fig. S5 provides additional informa-
tion on the functional validation of Plag1 and Lin28b genes as
downstream mechanistic effectors of Ezh2 loss and a proposed
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molecular model of its downstream effects. Table S1 lists the
causes of death for animals on the AML1-ETO9a maintenance
experiments. Table S2 lists the differentially expressed genes in
Ezh2+/+ MLL-AF9 mouse tumors treated with GSK343 (vs. DMSO).
Table S3 lists the differentially expressed genes in Ezh2+/+ vs.
Ezh2−/− Lin− BM cells (HSPCs). Table S4 lists the differentially
expressed genes in Ezh2+/+ vs. Ezh2−/− AML1-ETO9a BM cells.
Table S5 lists the differentially expressed genes in Ezh2+/+ vs.
Ezh2−/− MLL-AF9 BM cells. Table S6 lists the differentially bound
peaks for H3K27me3 between Ezh2+/+ and Ezh2−/− BM HSPCs.
Table S7 lists the differentially bound peaks for H3K4me3 be-
tween Ezh2+/+ and Ezh2−/− BM HSPCs. Table S8 lists the differ-
entially bound peaks for H3K27Ac between Ezh2+/+ and Ezh2−/−
BM HSPCs.
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